As an example, TMPRSS2-ERG fusion has been exploited for prostate cancer screening purposes [7], fusions involving MLL gene have been considered for Acute Myeloid Leukemia (AML) treatment stratification [8], RUNX1-RUNX1T1 fusion has been used for AML diagnosis according to World Health Organization (WHO) classifications [9], and PML-RARA fusion for monitoring minimal residual disease after treatment in adult AML [10]. Here, TMPRSS2 is linked to prostate cancer.